Publications by authors named "U Trafojer"
Background: The early use of broad-spectrum antibiotics remains the cornerstone for the treatment of neonatal late onset sepsis (LOS). However, which antibiotics should be used is still debatable, as relevant studies were conducted more than 20 years ago, recruited in single centres or countries, evaluated antibiotics not in clinical use anymore and had variable inclusion/exclusion criteria and outcome measures. Moreover, antibiotic-resistant bacteria have become a major problem in many countries worldwide.
View Article and Find Full Text PDFBackground: Sickle cell disease (SCD) is a chronic multisystem disorder requiring comprehensive care that includes newborn screening (NBS) as the first step of care. Italy still lacks a national SCD NBS program and policy on blood disorders. Pilot single-center screening programs and a regional targeted screening have been implemented so far, but more evidence is needed in order to impact health policies.
View Article and Find Full Text PDFBackground: Sepsis and bacterial meningitis are major causes of mortality and morbidity in neonates and infants. Meropenem, a broad-spectrum antibiotic, is not licensed for use in neonates and infants below 3 months of age and sufficient information on its plasma and CSF disposition and dosing in neonates and infants is lacking.
Objectives: To determine plasma and CSF pharmacokinetics of meropenem in neonates and young infants and the link between pharmacokinetics and clinical outcomes in babies with late-onset sepsis (LOS).
Antimicrobial prescriptions in neonatal intensive care units (NICUs) represent a point of concern for the emergence of MDROs and for morbidity associated with prolonged antibiotic exposure (e.g., invasive candidiasis, necrotizing enterocolitis, and late-onset sepsis).
View Article and Find Full Text PDFArticle Synopsis
- Late onset neonatal sepsis (LOS) poses high mortality risks, and the study aimed to assess new clinical criteria for better management and antibiotic effectiveness in Europe.
- The study involved 113 infants, with most cases being culture-proven, revealing a 61% success rate for the expert panel's diagnostic criteria.
- Findings highlighted significant variability in current antibiotic treatments, with 8% mortality and 45% failure rates, emphasizing the need for standardized, evidence-based guidelines.